leisure time -WSS

leisure time

author：focus 2025-09-30 08:52:10 - browse：5632

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Philips to halt sales of sleep apnea machines in U.S.

knowledge

WSS

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

RaDonda Vaught links Vanderbilt hospital issues to patient death

Philips to halt sales of sleep apnea machines in U.S.

EPA limits use of carcinogenic gas for sterilizing medical devices

Humana’s losses in Medicare Advantage tank its stock

Wikipedia

leisure time

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare coverage of Wegovy, once blocked, now looks possible

State Dept. review finds Biden bears some blame for Afghanistan failures

Merck, Johnson & Johnson CEOs will testify on high drug prices

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to save health care price transparency rules

Medical leaders decry Supreme Court decision on affirmative action

Reconstructing family trees of blood cells may help predict disease

Medicare proposal to cover medical devices draws a mixed reaction

EPA limits use of carcinogenic gas for sterilizing medical devices

entertainment

Why depression after traumatic brain injury is distinct

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Humana’s losses in Medicare Advantage tank its stock

Change Healthcare outage fallout shows need for new oversight

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Change Healthcare outage fallout shows need for new oversight

knowledge

entertainment

knowledge

hotspot